6-甲基-2,5-庚二酮 | 13901-85-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 6-甲基-2,5-庚二酮
• 英文名称: 6-methyl-2,5-heptanedione
• 英文别名: 6-methyl-heptane-2,5-dione；6-Methyl-heptan-2,5-dion；1.1-Dimethyl-acetonylaceton；α-Acetyl-p-isobutyryl-aethan；ω-Dimethyl-laevulinsaeuremethylketon；β.ε-Dioxo-ζ-methyl-heptan；ω.ω-Dimethyl-acetonylaceton；2-methyl-3,6-heptanedione；6-Methylheptane-2,5-dione
• CAS: 13901-85-4
• 化学式: C₈H₁₄O₂
• mdl: MFCD16706896
• 分子量: 142.198
• InChiKey: GQOZVBVPTAONFU-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：
  存在于烤烟烟叶、白肋烟烟叶和香料烟烟叶中。

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

制备方法与用途

制备方法

• 烟草: BU,56; FC,BU,OR,18; FC,40。

合成制备方法

• 烟草：BU，56；FC，BU，OR，18；FC，40。

用途简介

反应信息

• 作为反应物：
  描述：

  6-甲基-2,5-庚二酮 在 硫酸 作用下， 生成 5-methyl-2-(1-methylethyl)furan
  参考文献：
  名称：

  Dehydrocineoles. I. The Preparation of 2-Isopropyl-5-methylfuran and its Condensation with Maleic Anhydride

  摘要：

  DOI：

  10.1021/ja01310a044
• 作为产物：
  描述：

  trans-ascaridol glycol 生成 6-甲基-2,5-庚二酮
  参考文献：
  名称：

  Nelson, Journal of the American Chemical Society, 1913, vol. 35, p. 87

  摘要：

  DOI：

文献信息

• Surface Modifications and Methods for their Synthesis and Use
  申请人：McGall Glenn H.

  公开号：US20110143966A1

  公开（公告）日：2011-06-16

  Novel processes are disclosed for forming an array of polymers by functionalizing the surface of particles by methods that include covalently attaching a functionalized silicon compound. Substrates such as microparticles having functionalized silicon compounds attached thereto are produced by introducing at least one carboxyl group directly by silanating a carboxylated silane compound to the surface of a microparticle. In a further aspect of the invention, the silane compound is a dipodal carboxylated silane.

  本发明公开了用于形成聚合物阵列的新颖工艺，包括通过共价连接功能化硅化合物来功能化粒子表面。通过向微粒子表面引入至少一个羧基团，直接将羧基化硅烷化合物偶联到微粒子表面，从而生产出附着有功能化硅化合物的基材，例如微粒子。在本发明的另一方面，所述硅烷化合物是双官能团羧基硅烷。
• LXR AGONISTS AND USES THEREOF
  申请人：Martinez Eduardo J.

  公开号：US20170066791A1

  公开（公告）日：2017-03-09

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

  这项发明涉及调节肝X受体活性的化合物，包括该发明的化合物的药物组合物，以及利用这些组合物调节肝X受体活性治疗癌症的方法。
• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。